Health insurers offer coverage for pre-existing diseases like diabetes, hypertension, and asthma from Day 1. Key features ...

Looking for herbs that can lower your blood pressure? In this video, we'll show you a list of herbs that can help to lower your blood pressure. Herbal medicine is a great way to find relief from ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The U.S. Food and Drug Administration has approved George Medicines' Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.

A new era of hypertension treatment is on the horizon for U.S. patients with the FDA approval of George Medicines’ Widaplik, a three-in-one pill that can serve as an initial treatment to help ...

The FDA approved the first polypill designed for initial treatment of hypertension. Approval was based on the results of two positive studies presented at the European Society of Cardiology Congress.

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia ...

A novel treatment, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in individuals with uncontrolled or resistant hypertension, a global phase 3 trial showed.

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and ...

“The Launch-HTN trial is the largest phase 3 hypertension study with a novel drug. We tested lorundostat in a large, diverse patient population recruited globally, and found that it has a good ...

The results are a major milestone toward delivering the first targeted aldosterone synthase inhibitor treatment for uncontrolled or resistant hypertension, which could benefit millions of people ...